# Clinical characteristics of human parvovirus B19 infection after allogeneic stem cell transplantation

## TL;DR

This study examines the clinical features and outcomes of human parvovirus B19 infection in patients who underwent allogeneic stem cell transplantation.

## Contribution

The study provides a retrospective analysis of clinical manifestations and treatment outcomes of HPVB19 infection following allo-HSCT.

## Key findings

- 22 out of 24 patients with HPVB19 infection after allo-HSCT experienced anemia with a median HGB of 77.5 g/L.
- 13 patients (54.2%) had new-onset anemia or persistent HGB decline after transplantation.
- Treatment with intravenous immunoglobulin and/or antiviral therapy improved HGB levels in 76.92% of cases.

## Abstract

人细小病毒B19（HPVB19）属细小病毒科，红细胞病毒属，与多种人类疾病相关，HPVB19感染是异基因造血干细胞移植（allo-HSCT）后难治性贫血的重要原因之一。此项研究对24例HSCT合并HPVB19感染的患者进行了回顾性分析，旨在整理总结allo-HSCT术后合并HPVB19感染患者的临床表现、治疗与转归，为allo-HSCT后HPVB19感染的管理提供经验。HPVB19感染患者中位年龄为25岁，感染发生的中位时间为移植后107 d（+107 d），有22例（91.7％）患者存在贫血，HGB中位数为77.5（46～149）g/L；新发贫血或血红蛋白持续下降的患者有13例（54.2％）。患者的中位住院时长为19 d，在新发贫血或HGB持续下降的患者中，经过静脉丙种球蛋白和（或）抗病毒治疗后HGB平均升高15.69 g/L，10例（76.92％）患者治疗有效。HSCT后出现难治性贫血时应警惕HPVB19感染；尽管缺乏特异性的治疗手段，HPVB19感染患者总体预后较好。